How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model
Metadatos
Afficher la notice complèteEditorial
BMC
Materia
APOE ε4 Alzheimer’s disease Physical activity Amyloid pathology Tau pathology Cerebrovascular health Neurotrophic factors Neuroinflammation Glucose metabolism Mitochondrial dysfunction
Date
2023-01-27Referencia bibliográfica
de Frutos Lucas, J... [et al.]. How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model. Alz Res Therapy 15, 22 (2023). [https://doi.org/10.1186/s13195-023-01170-4]
Patrocinador
Ministry of Science and Innovation, Spain (MICINN) Spanish Government PRE2019-087612Résumé
Background Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD).
On the other hand, the apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor for developing
AD. Extensive research has been conducted to determine whether frequent PA can mitigate the increased AD
risk associated with APOE ε4. However, thus far, these attempts have produced inconclusive results. In this context,
one possible explanation could be that the influence of the combined effect of PA and APOE ε4 carriage might be
dependent on the specific outcome measure utilised.
Main body.
In order to bridge these discrepancies, the aim of this theoretical article is to propose a novel model on the interactive
effects of PA and APOE ε4 carriage on well-established mechanisms underlying AD. Available literature was searched
to investigate how PA and APOE ε4 carriage, independently and in combination, may alter several molecular pathways
involved in AD pathogenesis. The reviewed mechanisms include amyloid beta (Aβ) and tau deposition and clearance,
neuronal resilience and neurogenesis, lipid function and cerebrovascular alterations, brain immune response
and glucose metabolism. Finally, combining all this information, we have built an integrative model, which includes
evidence-based and theoretical synergistic interactions across mechanisms. Moreover, we have identified key knowledge
gaps in the literature, providing a list of testable hypotheses that future studies need to address.
Conclusions We conclude that PA influences a wide array of molecular targets involved in AD neuropathology. A
deeper understanding of where, when and, most importantly, how PA decreases AD risk even in the presence of the
APOE ε4 allele will enable the creation of new protocols using exercise along pharmaceuticals in combined therapeutic
approaches.